This week we open with a critical take on our current system of disseminating scientific research, specifically focusing on the prevalence of -- and dependence on -- medical writers. In the second half of the episode, we interview Dr. Allen Pannell of the Haslam College of Business at the University of Tennessee on using a Frequentist approach vs a Bayesian approach in the context of a single clinical trial.

Frequentist vs Bayesian: doi.org/10.1136/bmjopen-2018-024256

Dr. Pannell's breast cancer support group: https://www.breastconnect.org/

Dr. Pannell's research project: http://tinyurl.com/peerErPrHer2

Back us on Patreon! www.patreon.com/plenarysession

In this BONUS episode we give advice on how to use Twitter effectively: how to focus your content, how to build your Twitter following, and how to conceptualize of the platform as an information network.

Back us on Patreon! www.patreon.com/plenarysession

This week we discuss the recent paper "Interpreting the Effectiveness of Cancer Screening From National Population Statistics: Is It Sound Practice?" with its author, Dr. Joaquín Chapa of OHSU. We then revisit the POLO trial with Dr. Emerson Chen of OHSU, who disagrees with last episode's analysis.

Effectiveness of Screening: doi.org/10.1016/j.mayocp.2019.02.016

POLO: doi.org/10.1056/NEJMoa1903387

Back us on Patreon! www.patreon.com/plenarysession

This week we cover some of the highlights from this year's ASCO annual meeting. We discuss the POLO study "Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer" and the TITAN study "Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer", both recently published in NEJM. We end with a presentation titled "Expedited Program Use and Patient Experience in Trials", which was given in a shortened version at ASCO.

POLO: doi.org/10.1056/NEJMoa1903387

TITAN: doi.org/10.1056/NEJMoa1903307

Back us on Patreon! www.patreon.com/plenarysession

We begin this episode by responding to listener feedback from episode 1.61's discussion of clinic appointment time and rates of cancer screening. We also tackle listeners' outcry over our take-down of BILCAP (spoiler alert: BILCAP is still a null trial) and how outcry like this highlights the need to train clinicians to think probabilistically. From there, we move on to discussing the recent paper by Myung Sun Kim in JAMA Network Open on waterfall plots and how they are a visual distortion of response rate. We end the episode with an interview with Dr. Jeff Sharman of Willamette Valley Cancer Institute in Eugene, Oregon on community oncology, enrolling patients in clinical trials, expertise of academia, and using real-world evidence.

Waterfall plots: doi.org/10.1001/jamanetworkopen.2019.3981

Back us on Patreon! www.patreon.com/plenarysession

This week we cover three papers -- "Postpublication Metrics of Randomized Clinical Trials With and Without Null Findings" by Murray et al. in JAMA, "Association of Primary Care Clinic Appointment Time With Clinician Ordering and Patient Completion of Breast and Colorectal Cancer Screening" by Hsiang et al. in JAMA Network Open, and "Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers" by Drilon et al. in Molecular Case Studies. We end with an interview with Dr. Christopher Booth of Queens University in Kingston, Ontario, conducted in the Plenary Session Mobile Command Unit.

Postpublication Metrics: doi.org/10.1001/jama.2019.2994

PCP Appointment Time: doi.org/10.1001/jamanetworkopen.2019.3403

Exceptional Responders: doi.org/10.1101/mcs.a003665

Back us on Patreon! www.patreon.com/plenarysession

We revisit I-PREDICT, discuss the "Imputability of Adverse Events to Anticancer Drugs" (a letter published recently in the New England Journal of Medicine), and interview Dr. Daniel Hartung of Oregon State University's College of Pharmacy on his vast knowledge of the cost of drugs, specifically addressing Acthar gel and multiple sclerosis drugs.

Imputability of Adverse Events: doi.org/10.1056/NEJMc1900053

Back us on Patreon! www.patreon.com/plenarysession

In this BONUS episode, we interview Palmer Greene, a fourth-year medical student at the University of Chicago Pritzker School of Medicine, on his recent paper: "Should Evidence Come with an Expiration Date?", published in the Journal of General Internal Medicine.

Expiration Date?: doi.org/10.1007/s11606-019-05032-4

Back us on Patreon! www.patreon.com/plenarysession

This week we discuss three paired papers on precision oncology published in Nature Medicine and then, later in the episode, go in-depth on the implications of these negative studies with Dr. Talal Hilal of the Mayo Clinic. We also discuss the use of magic mouthwash for oral mucositis with Plenary Session fan, Dr. Arjun Gupta of Johns Hopkins University.

WINTHER: doi.org/10.1038/s41591-019-0424-4

TARGET: doi.org/10.1038/s41591-019-0380-z

I-PREDICT: doi.org/10.1038/s41591-019-0407-5

Magic mouthwash: doi.org/10.1001/jamainternmed.2018.6223

Back us on Patreon! www.patreon.com/plenarysession

In this BONUS episode, we interview Dr. Talal Hilal of the Mayo Clinic on his paper that was published today in JAMA Oncology, titled "Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration".

Control Arm Quality: doi.org/10.1001/jamaoncol.2019.0167

Back us on Patreon! www.patreon.com/plenarysession